RxDoctor Payments Data

Jonathan Humphrey, MD

Family Medicine · Danville, CANPI 1689644866

Payments from drug & device makers

$18,265in general payments, 2019–2025

Across 973 payments — averaging $18.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Pfizer$1K
  • Amgen$1K
  • GSK$839
  • Esperion Therapeutics, Inc.$687
  • AstraZeneca$652
  • plus $10K from 54 others

What the payments were for

  • Food & beverage$18,17199%
  • Education$951%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)190$2,603
Pfizer74$1,423
Amgen(2 entities)54$1,127
GSK53$839
Esperion Therapeutics, Inc.34$687
AstraZeneca36$652
Supernus Pharmaceuticals, Inc.4$628
Boehringer Ingelheim32$594
Otsuka America Pharmaceutical, Inc.27$571
Johnson & Johnson33$515
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC27$512
Novartis32$489
Novo Nordisk25$468
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)14$334
Lilly USA, LLC18$293
Antares Pharma, Inc.16$268
Biohaven Pharmaceutical Holding Company Ltd.11$255
Bayer12$254
Teva Pharmaceuticals USA, Inc.11$249
Astellas Pharma US Inc10$241
Takeda Pharmaceuticals U.S.A., Inc.17$229
Ironshore Pharmaceuticals Inc.12$228
Merck13$219
Neurocrine Biosciences, Inc.9$209
Bausch Health US, LLC13$208
Sanofi-aventis U.S. LLC12$203
Lundbeck LLC10$197
Biohaven Pharmaceuticals, Inc.7$191
Corium, LLC8$182
BD2$175
Axsome Therapeutics, Inc.6$170
Eisai Inc.10$160
IBSA Pharma Inc.7$159
Sumitomo Pharma America, Inc.7$155
E.r. Squibb & Sons, L.L.C.3$154
Exact Sciences7$152
Adlon Therapeutics L.p.7$135
Sanofi Pasteur Inc.7$132
Regeneron Healthcare Solutions, Inc.7$123
Alfasigma USA, Inc.5$97
Abbott4$94
Alkermes, Inc.4$92
Verity Pharmaceuticals Inc.4$82
Biogen3$79
Arbor Pharmaceuticals, Inc.5$75
Nestle Healthcare Nutrition Inc.3$64
Almatica Pharma LLC2$62
Indivior Inc.3$62
Vanda Pharmaceuticals Inc.2$61
Amarin Pharma, Inc.4$60
Therapeuticsmd, Inc.4$59
Currax Pharmaceuticals LLC4$57
VBI Vaccine (delaware) Inc.3$51
Acadia Pharmaceuticals Inc2$50
Tris Pharma Inc2$40
Sanofi1$39
Phathom Pharmaceuticals, Inc.2$39
Dynavax Technologies Corporation4$39
Harmony Biosciences LLC2$37
Ultragenyx Pharmaceutical Inc.2$37

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,265 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$508,608
Medicare patients
815
Services billed
21,136

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide153$172,026
OzempicSemaglutide93$110,661
Repatha SureclickEvolocumab123$110,215
EliquisApixaban64$73,066
JardianceEmpagliflozin46$62,603
ArexvyRsvpref3 Antigen/As01e/Pf169$52,477
RybelsusSemaglutide32$50,157
XareltoRivaroxaban29$31,860
RexultiBrexpiprazole13$28,057
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$27,398
ShingrixVaricella-Zoster Ge/As01b/Pf109$24,315
Praluent PenAlirocumab37$20,832
LinzessLinaclotide24$20,587
CreonLipase/Protease/Amylase11$15,832
MyrbetriqMirabegron18$13,691

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$293$172,026153 claims
Novo NordiskOzempic, Rybelsus$468$160,817125 claims
GSKArexvy, Trelegy Ellipta, Shingrix, Twinrix$839$106,411337 claims
PfizerEliquis, Premarin$1,423$80,17883 claims
Boehringer IngelheimJardiance$594$62,60346 claims
AbbVieLinzess, Creon, Synthroid$2,603$44,644116 claims
Johnson & JohnsonXarelto$515$31,86029 claims
Otsuka America Pharmaceutical, Inc.Rexulti$571$28,05713 claims
Arbor Pharmaceuticals, Inc.Horizant, Edarbi$75$21,22234 claims
Astellas Pharma US IncMyrbetriq$241$13,69118 claims
AstraZenecaFarxiga$652$7,17613 claims
MerckBelsomra$219$6,05812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Danville

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →